丙戊酸镁缓释片治疗精神分裂症的辅助作用

A study of magnesium valproate extended release tablets with aripiprazole in treatment of refractory schizophrenia

目的:探讨阿立哌唑合用丙戊酸镁缓释片治疗难治性精神分裂症患者的疗效及安全性。方法:60例难治性精神分裂症患者随机分为两组,分别给予阿立哌唑合用丙戊酸镁缓释片与阿立哌唑单用治疗,疗程8周。用阳性与阴性症状量表(PANSS)和治疗中出现的症状量表(TESS)评定疗效和不良反应。结果:阿立哌唑合用丙戊酸镁缓释片治疗难治性精神分裂症的疗效优于单用阿立哌唑(P<0.05);两组不良反应差异无统计学意义(P>0.05)。结论:阿立哌唑合用丙戊酸镁缓释片治疗难治性精神分裂症疗效好,安全性好。

Objective：To evaluate the curative effect and saefty of magnesium valproate extended release tablets combined with aripiprazole in the treatment of refractory schizophrenia. Method：60 inpatients with refractory schizophrenia were divided into combined group and single group, which were treated with magnesium valproate sustained-release tablets augmented with aripiprazole or only aripiprazole for 8 weeks. PANSS and TESS were used to evaluate the efficacy and side effects respectively. Results： Combined treatment of magnesium valproate extended release tablets with aripiprazole showed superior efficacy than aripiprazole only. There was no significant difference in side effects between the two groups. Conclusion： Magnesium valproate sustained release tablets augmented with aripiprazole shows better curative effect and less side effect than aripiprazole in treating refractory schizophrenia.